Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Abstract KRAS mutations represent the most common driver genetic alterations in multiple malignant tumors, particularly exerting well-defined oncogenic driver roles in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The recent success of KRAS G12C mutation-specif...
Kaydedildi:
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer
2025-10-01
|
| Seri Bilgileri: | Discover Oncology |
| Konular: | |
| Online Erişim: | https://doi.org/10.1007/s12672-025-03569-x |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|